NantHealth Inc (NH) Upgraded to Hold at Zacks Investment Research
NantHealth Inc (NYSE:NH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.
According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “
Other analysts also recently issued reports about the stock. Canaccord Genuity restated a “buy” rating and issued a $17.00 target price on shares of NantHealth in a report on Monday, September 19th. FBR & Co reaffirmed a “buy” rating on shares of NantHealth in a research note on Thursday, August 18th. Jefferies Group began coverage on shares of NantHealth in a research note on Monday, June 27th. They set a “buy” rating for the company. Cowen and Company began coverage on shares of NantHealth in a research note on Monday, June 27th. They set an “outperform” rating and a $19.00 price target for the company. Finally, First Analysis began coverage on shares of NantHealth in a research note on Monday, June 27th. They set an “overweight” rating and a $18.00 price target for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $18.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/nanthealth-inc-nh-upgraded-to-hold-at-zacks-investment-research.html
NantHealth (NYSE:NH) opened at 13.67 on Wednesday. The firm’s 50 day moving average is $13.16 and its 200-day moving average is $12.69. NantHealth has a 52 week low of $9.79 and a 52 week high of $16.63. The company’s market cap is $1.66 billion.
NantHealth (NYSE:NH) last posted its earnings results on Tuesday, August 9th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.26. The business earned $31.50 million during the quarter, compared to the consensus estimate of $23.55 million. The business’s revenue was up 166.9% on a year-over-year basis. On average, analysts predict that NantHealth will post ($0.59) earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in NH. Wildcat Capital Management LLC bought a new stake in NantHealth during the second quarter valued at about $3,008,000. Jefferies Group LLC bought a new stake in NantHealth during the second quarter valued at about $6,943,000. Blackstone Group L.P. bought a new stake in NantHealth during the second quarter valued at about $7,463,000. Finally, FMR LLC bought a new stake in NantHealth during the second quarter valued at about $11,250,000.
NantHealth Company Profile
NantHealth, Inc, formerly Nant Health, LLC, is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.